Equities
Take Survey
Help shape our future virtual events & community services
Take part in our survey for a chance to win a free 3-month standard gift subscription.

Profile data is unavailable for this security.

About the company

Koninklijke Philips N.V. is the Netherlands-based health technology company. The Company's segments include Personal Health businesses, Diagnosis & Treatment businesses, Connected Care & Health Informatics businesses, HealthTech Other and Legacy Items. The Personal Health businesses segment is engaged in the health continuum, delivering integrated, connected solutions that support healthier lifestyles and those living with chronic disease. The Diagnosis & Treatment businesses segment delivers precision medicine and treatment, and therapy. The Connected Care & Health Informatics businesses segment provides consumers, care givers and clinicians with digital solutions that facilitate care by enabling precision medicine and population health management. The HealthTech Other segment comprises such items, as innovation, emerging businesses, royalties, among others. The Legacy Items segment consists mainly of separation costs, legacy legal items, legacy pension costs, among others.

  • Revenue in EUR (TTM)19.04bn
  • Net income in EUR973.00m
  • Incorporated2000
  • Employees77.08k
  • Location
    Koninklijke Philips NVBreitner Center, Amstelplein 2AMSTERDAM 1096 BCNetherlandsNLD
  • Phone+31 205977777
  • Fax+31 205977220
  • Websitehttps://www.philips.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PHIA:AEX since
announced
Transaction
value
Capsule Technologies IncAnnounced19 Jan 202119 Jan 2021Announced-10.80%635.00m
Data delayed at least 15 minutes, as of Sep 16 2021 16:39 BST.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
image